Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based MedaSorb Technologies has acquired ownership of two patents that will broaden the core technology related to CytoSorb polymer hemocompatibility and methods of manufacture, from Robert Albright, a scientific consultant to the company.
Subscribe to our email newsletter
MedaSorb’s commercialization plan calls for CytoSorb to first enter the market in Europe and then in the US, followed by its pipeline of additional products. MedaSorb is initiating a multi-center trial that will enroll up to 80 patients in Germany as a part of their application for the European CE Mark. The CE Mark will allow MedaSorb to market CytoSorb in the EU. The clinical study will utilize CytoSorb as an adjunctive therapy in patients with acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) in the setting of sepsis.
Al Kraus, CEO of MedaSorb, said: “We are pleased to complete the assignment of these important patents to our intellectual property portfolio. This technology expansion further strengthens MedaSorb’s intellectual property portfolio, and increases our total patent portfolio of issued patents to 24.”